MIRZYME_THERAPEUTICS_LIMI - Accounts

Company Registration No. 10133310 (England and Wales)
MIRZYME THERAPEUTICS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021
PAGES FOR FILING WITH REGISTRAR
MIRZYME THERAPEUTICS LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2021
31 December 2021
- 1 -
2021
2020
Notes
£
£
£
£
Fixed assets
Intangible assets
4
301,726
267,478
Current assets
Debtors
5
3,171
4,558
Cash at bank and in hand
1,079,061
1,173,227
1,082,232
1,177,785
Creditors: amounts falling due within one year
6
(68,126)
(62,134)
Net current assets
1,014,106
1,115,651
Net assets
1,315,832
1,383,129
Capital and reserves
Called up share capital
100
100
Share premium account
1,516,000
1,516,000
Profit and loss reserves
(200,268)
(132,971)
Total equity
1,315,832
1,383,129

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 December 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 22 September 2022 and are signed on its behalf by:
Prof A S Ahmed
Director
Company Registration No. 10133310
MIRZYME THERAPEUTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021
- 2 -
1
Accounting policies
Company information

Mirzyme Therapeutics Limited is a private company limited by shares incorporated in England and Wales. The registered office is Faraday Wharf, Innovation Birmingham Campus, Holt Street, Birmingham, West Midlands, B7 4BB.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

This company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the requirement to present a statement of cash flow and related notes and disclosures;

1.2
Intangible fixed assets other than goodwill

Intangible assets acquired are recognised at cost and are subsequently measured at cost less accumulated amortisation and any accumulated impairment losses.

 

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Patents
Amortised on a straight line basis over the patent life
1.3
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.4
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

MIRZYME THERAPEUTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021
1
Accounting policies
(Continued)
- 3 -
1.5
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.6
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.7
Derivatives

Derivatives are initially recognised at fair value at the date a derivative contract is entered into and are subsequently remeasured to fair value at each reporting end date. The resulting gain or loss is recognised in profit or loss immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in profit or loss depends on the nature of the hedge relationship.

 

A derivative with a positive fair value is recognised as a financial asset, whereas a derivative with a negative fair value is recognised as a financial liability.

MIRZYME THERAPEUTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021
1
Accounting policies
(Continued)
- 4 -
1.8
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2021
2020
Number
Number
Total
3
3
MIRZYME THERAPEUTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021
- 5 -
4
Intangible fixed assets
Other
£
Cost
At 1 January 2021
302,978
Additions
57,978
At 31 December 2021
360,956
Amortisation and impairment
At 1 January 2021
35,500
Amortisation charged for the year
23,730
At 31 December 2021
59,230
Carrying amount
At 31 December 2021
301,726
At 31 December 2020
267,478
5
Debtors
2021
2020
Amounts falling due within one year:
£
£
Other debtors
3,171
4,558
6
Creditors: amounts falling due within one year
2021
2020
£
£
Trade creditors
9,829
6,488
Taxation and social security
576
-
0
Other creditors
57,721
55,646
68,126
62,134
2021-12-312021-01-01false22 September 2022CCH SoftwareCCH Accounts Production 2022.200No description of principal activityProf A S AhmedDr S O HayatM E Vousden101333102021-01-012021-12-31101333102021-12-31101333102020-12-3110133310core:IntangibleAssetsOtherThanGoodwill2021-12-3110133310core:IntangibleAssetsOtherThanGoodwill2020-12-3110133310core:CurrentFinancialInstrumentscore:WithinOneYear2021-12-3110133310core:CurrentFinancialInstrumentscore:WithinOneYear2020-12-3110133310core:CurrentFinancialInstruments2021-12-3110133310core:CurrentFinancialInstruments2020-12-3110133310core:ShareCapital2021-12-3110133310core:ShareCapital2020-12-3110133310core:SharePremium2021-12-3110133310core:SharePremium2020-12-3110133310core:RetainedEarningsAccumulatedLosses2021-12-3110133310core:RetainedEarningsAccumulatedLosses2020-12-3110133310bus:Director12021-01-012021-12-3110133310core:IntangibleAssetsOtherThanGoodwill2021-01-012021-12-3110133310core:PatentsTrademarksLicencesConcessionsSimilar2021-01-012021-12-31101333102020-01-012020-12-3110133310core:IntangibleAssetsOtherThanGoodwill2020-12-3110133310core:WithinOneYear2021-12-3110133310core:WithinOneYear2020-12-3110133310bus:PrivateLimitedCompanyLtd2021-01-012021-12-3110133310bus:SmallCompaniesRegimeForAccounts2021-01-012021-12-3110133310bus:FRS1022021-01-012021-12-3110133310bus:AuditExempt-NoAccountantsReport2021-01-012021-12-3110133310bus:Director22021-01-012021-12-3110133310bus:Director32021-01-012021-12-3110133310bus:FullAccounts2021-01-012021-12-31xbrli:purexbrli:sharesiso4217:GBP